Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer

Oncologist

Volumn 17, Issue 9, 2012, Pages 1191-1197

  Hanna, Nader ^a   Bikov, Kaloyan A ^b   McNally, Diane ^b   Onwudiwe, Nneka C ^b   Dalal, Mehul ^c   Daniel Mullins, C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c SANOFI   (France)

Author keywords

Chemotherapy; Colon cancer; Deep vein thrombosis; Venous thromboembolism

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; COMORBIDITY; FEMALE; FOLLOW UP; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84866554935     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0093     Document Type: Article

References (40)

1. Nordstrom M, Lindblad B, Anderson H et al. Deep venous thrombosis and occult malignancy: An epidemiological study. BMJ 1994;308:891-894.
2. White RH, Chew HK, Zhou H et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005;165: 1782-1787.
3. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: Epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003;70:7-30.
4. Alcalay A, Wun T, Khatri V et al. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 2006;24: 1112-1118.
5. Sorensen HT, Mellemkjaer L, Steffensen FH et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998;338:1169-1173.
6. Heit JA, O'Fallon WM, Petterson TM et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med 2002;162:1245-1248.
7. Darze ES, Latado AL, Guimaraes AG et al. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:2576-2580.
8. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
9. Schulman S, Ogren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006;96:258-266.
10. Baron JA, Gridley G, Weiderpass E et al. Venous thromboembolism and cancer. Lancet 1998;351:1077-1080.
11. Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768.
12. Chew HK, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166:458-464.
13. van Dongen CJ, Vink R, Hutten BA et al. The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: A meta-analysis. Arch Intern Med 2003;163:1285-1293.
14. Lee AY, Levine MN. Venous thromboembolism and cancer: Risks and outcomes. Circulation 2003;107: 17-21.
15. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839-4847.
16. Khorana AA, Francis CW, Culakova E et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-2346.
17. Kroger K, Weiland D, Ose C et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.
18. Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.
19. Khorana AA. The NCCN clinical practice guidelines on venous thromboembolic disease: Strategies for improving VTE prophylaxis in hospitalized cancer patients. The Oncologist 2007;12:1361-1370.
20. Donati MB. Cancer and thrombosis. Haemostasis 1994;24:128-131.
21. Agnelli G, Bolis G, Capussotti L et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg 2006;243:89-95.
22. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.
23. Chew HK, Wun T, Harvey DJ et al. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-76.
24. Sorensen HT, Mellemkjaer L, Olsen JH et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.
25. Martino MA, Williamson E, Siegfried S et al. Diagnosing pulmonary embolism: Experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol 2005;98:289-293.
26. Heit JA. Cancer and venous thromboembolism: Scope of the problem. Cancer Control 2005;12 Suppl 1:5-10.
27. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapyassociated thrombosis. Blood 2008;111: 4902-4907.
28. Khorana AA, Francis CW, Culakova E et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829.
29. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-568.
30. Blom JW, Doggen CJ, Osanto S et al. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005;3:2471-2478.
31. Mandala M, Barni S, Floriani I et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The GISCAD-alternating schedule study findings. Eur J Cancer 2009;45:65-73.
32. Otten HM, Mathijssen J, Cate H et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: An underestimated phenomenon. Arch Intern Med 2004;164:190-194.
33. Kakkar AK, Levine M, Pinedo HM et al. Venous thrombosis in cancer patients: Insights from the FRONTLINE survey. The Oncologist 2003;8:381-388.
34. Cohen AT, Tapson VF, Bergmann JF et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008;371: 387-394.
35. Tapson VF, Decousus H, Pini M et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: Findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936-945.
36. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: A necropsy review. J Clin Pathol 2004;57:1254-1257.
37. Black WC, Haggstrom DA, Welch HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002;94:167-173.
38. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21: 2912-2919.
39. Gross CP, Galusha DH, Krumholz HM. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J Gen Intern Med 2007; 22:321-326.
40. Agnelli G, George DJ, Kakkar AK et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012;366: 601-609.